RxDoctor Payments Data

Saad Tabbara, MD

Interventional Cardiology · Pittsburgh, PANPI 1518993542

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 47.1% of the total. Reporting peaked in 2023 at $10,589 and has fallen 50.8% since, to $5,209 in 2025.

$28,118in general payments, 2019–2025

Across 302 payments — averaging $93.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13K
  • Edwards Lifesciences$3K
  • Medtronic$2K
  • Penumbra, Inc.$2K
  • Teleflex LLC$2K
  • Abbott$1K
  • plus $5K from 27 others
$327,558in research payments, 2019–2025

Across 25 payments — averaging $13,102 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$326K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K

What the payments were for

  • Consulting fees$1481%
  • Speaking & faculty fees$12,00043%
  • Grants$550%
  • Travel & lodging$3,55813%
  • Food & beverage$12,35744%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,118 in reported general payments places this provider in the 80th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$129,978
Medicare patients
783
Services billed
1,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$113,035
EntrestoSacubitril/Valsartan118$82,515
XareltoRivaroxaban61$46,551
JardianceEmpagliflozin25$18,137
FarxigaDapagliflozin Propanediol26$16,583
Repatha SureclickEvolocumab25$13,759
BrilintaTicagrelor14$7,751
Ranolazine ErRanolazine89$5,070
Atorvastatin Calcium276$3,930
Varenicline Tartrate13$3,891
Icosapent Ethyl18$3,871
Valsartan146$3,531
Ezetimibe208$2,979
Propafenone Hcl ErPropafenone Hcl17$2,570
Rosuvastatin Calcium144$2,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$113,035133 claims
NovartisEntresto$394$82,515118 claims
Johnson & JohnsonXarelto$195$46,55161 claims
AstraZenecaFarxiga, Brilinta$397$24,33440 claims
Boehringer IngelheimJardiance$58$18,13725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →